Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.40 |
| ▸ | MYC | P01106 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772067 | 0.81 | BRD4 (0.46) | CNR2CNR1 | |
| SCHEMBL23772104 | 0.78 | SCN9A (0.43) | SCN9ASCN5AMYC | |
| SCHEMBL23772066 | 0.76 | ALDH1A1 (0.42) | CNR2CNR1 | |
| SCHEMBL23772011 | 0.74 | L3MBTL1 (0.39) | CNR2CNR1 | |
| SCHEMBL23771973 | 0.73 | MYC (0.40) | SCN9ASCN5AMYC | |
| SCHEMBL23772004 | 0.72 | CNR2 (0.43) | CNR2CNR1 | |
| SCHEMBL23772031 | 0.72 | MYC (0.38) | SCN9ASCN5AMYC | |
| SCHEMBL23772005 | 0.71 | PRKAB2 (0.35) | SCN9ASCN5AMYC | |
| SCHEMBL23772068 | 0.70 | BRD4 (0.41) | CNR2CNR1 | |
| SCHEMBL3447226 | 0.69 | SCN9A (0.40) | CNR2CNR1SCN9ASCN5AMYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, CDV3, HMBS | CNR2 3045/4885CNR1 3699/4885SCN9A 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.